Overactive Bladder (OAB) Clinical Trial
Official title:
A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multi-Center Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)
The purpose of this study was to assess the efficacy, safety and tolerability of mirabegron versus placebo in the treatment of older adult subjects with OAB.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00507169 -
SVT-40776 in Patients Suffering From Overactive Bladder Syndrome
|
Phase 2 | |
Completed |
NCT02294396 -
Postmarketing Study to Evaluate add-on Therapy With Anticholinergics in Patients With Overactive Bladder (OAB) on Mirabegron.
|
Phase 4 | |
Completed |
NCT01936870 -
Drug Use Investigation for Toviaz
|
||
Completed |
NCT03846895 -
Vaginal CO2 Laser in Postmenopausal Women With Overactive Bladder Syndrome (OAB)
|
N/A | |
Completed |
NCT03903094 -
A Study on Anticholinergic Use: Attribution of Overactive Bladder (OAB) Medications to the Anticholinergic Burden
|
||
Terminated |
NCT04451382 -
PTNS vs Botox of Refractory OAB
|
||
Terminated |
NCT04641975 -
A Study to Evaluate Mirabegron in Pediatric Participants From 5 to Less Than 18 Years of Age With Overactive Bladder (OAB)
|
Phase 3 | |
Completed |
NCT00366002 -
Patient's Perception of Treatment Outcome With Darifenacin by Patients With Overactive Bladder
|
Phase 4 | |
Completed |
NCT02138747 -
A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants With Overactive Bladder (OAB)
|
Phase 4 | |
Completed |
NCT03602508 -
Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania
|
||
Completed |
NCT03572231 -
A Registry Study of Patients Initiating a Course of Drug Therapy for Overactive Bladder in Taiwan, Korea and China
|
||
Completed |
NCT05211193 -
Open Label Study to Evaluate the Efficacy of the Home Based Electrical Transcutaneous URIS I in the Treatment of Overactive Bladder (OAB).
|
||
Completed |
NCT04562090 -
A Study With Mirabegron 50 mg and 25 mg in Chinese Participants With Overactive Bladder
|
Phase 4 | |
Completed |
NCT00282932 -
Detrol LA In Men With Overactive Bladder.
|
Phase 4 | |
Completed |
NCT01639794 -
Vesitirimâ„¢ in Men Postmarketing Observational Study
|
N/A | |
Completed |
NCT00742833 -
A Phase II Study of KUC-7483 in Patients With Overactive Bladder
|
Phase 2 | |
Withdrawn |
NCT01317810 -
A Study Measuring and Tracking Changes in Overactive Bladder (OAB) Medication
|
N/A |